重组人干扰素α1b不同给药方式治疗小儿疱疹性咽峡炎的效果

Effect of Different Administration Methods of Recombinant Human Interferon α1b on Children with Herpes Angina

目的 分析通过不同的重组人干扰素α1b给药方式对小儿疱疹性咽峡炎进行治疗的效果。方法 选择在2018年12月至2019年8月到我院进行治疗的76例小儿疱疹性咽峡炎患儿,按随机方法分为观察组和对照组,每组38例。两组患儿在治疗过程中均通过重组人干扰素α1b进行用药,观察组以雾化吸入治疗,对照组以肌内注射治疗,对两组患儿经过不同用药之后的治疗有效率、用药不良反应发生率、临床恢复时间、心理健康状况、睡眠质量等进行统计学比较和分析。结果 观察组(37例,占比为97.37%)的治疗有效率比对照组(30例,占比为78.95%)更高(P<0.05)。观察组(1例,占比为2.63%)的用药不良反应发生率比对照组(11例,占比为28.95%)更低(P<0.05)。观察组用药以后的退热时间、疱疹消失时间、住院时间明显比对照组短(P<0.05)。用药前,两组患儿的CITSEA评分和对照组差异无统计学意义(P>0.05),用药后,观察组患儿的CITSEA评分改善的效果明显比对照组更好(P<0.05)。用药前,两组患儿的PSQI评分差异无统计学意义(P>0.05),用药后,观察组患儿的PSQI评分改善效果比对照组更为理想(P<0.05)。结论 对小儿疱疹性咽峡炎进行治疗时应用重组人干扰素α1b通过气泵吸入的治疗方法进行给药可以有效提高患者的治疗总有效率,且不会产生严重的不良反应,对促进患儿临床症状的改善发挥了重要作用,还可以有效的改善患儿的整体心理状态,提高其睡眠质量。

Objective To analyze the effect of different administration methods of recombinant human interferon α1b on children with herpetic angina. Methods A total of 76 children with herpetic angina who were treated in our hospital from December 2018 to August 2019 were selected and randomly divided into an observation group and a control group, with an average of 38 cases in each group. The two groups of children were treated with recombinant human interferon α1b during the treatment process, the observation group was treated by atomization inhalation, and the control group was treated by intramuscular injection. Statistical comparison and analysis were carried out on the rate, clinical recovery time, mental health status, and sleep quality. Results The treatment effective rate of the observation group(37 cases, accounting for 97.37%) was higher than that of the control group(30 cases, accounting for 78.95%)(P<0.05). The incidence of adverse drug reactions in the observation group(1 case,accounting for 2.63%) was lower than that in the control group(11 cases, accounting for 28.95%)(P<0.05). The observation group The antipyretic time, herpes disappearance time, and hospitalization time after the medication were significantly shorter than those in the control group(P<0.05).Before treatment, there was no significant difference between the CITSEA score between the two groups and the control group(P>0.05), after treatment, the improvement effect of CITSEA score of the observation group was significantly better than that of the control group(P<0.05).Before treatment, the PSQI of the two groups of children There was no significant difference in the scores(P>0.05). After treatment, the PSQI score improvement effect of the observation group was more ideal than that of the control group(P<0.05). Conclusion In the treatment of children with herpetic angina, the administration of recombinant human interferon α1b by air pump inhalation can effectively improve the total effective rate of patients’ treatment, and at the same time, it will not produce serious adverse reactions, which is beneficial to the clinical improvement of children.The improvement of symptoms plays an important role, and it can also effectively improve the overall psychological state and sleep quality of children.